

# Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

## CD45 Krome Orange

RRID:AB\_2888654

Type: Antibody

---

### Proper Citation

Beckman Coulter Cat# A96416, RRID:AB\_2888654

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2888654](http://antibodyregistry.org/AB_2888654)

**Proper Citation:** Beckman Coulter Cat# A96416, RRID:AB\_2888654

**Target Antigen:** CD45

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** CD45 Krome Orange

**Description:** This monoclonal targets CD45

**Target Organism:** human

**Clone ID:** J33

**Antibody ID:** AB\_2888654

**Vendor:** Beckman Coulter

**Catalog Number:** A96416

**Record Creation Time:** 20250819T225945+0000

**Record Last Update:** 20250820T035748+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD45 Krome Orange.

No alerts have been found for CD45 Krome Orange.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.

Zhang Y, et al. (2025) Dyslipidemia is associated with increased NK cell cytotoxicity and autoimmunity in women with recurrent pregnancy losses. *The Journal of clinical endocrinology and metabolism*.

Kaufman B, et al. (2025) N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1. *Molecular cancer*, 24(1), 140.

Lindahl H, et al. (2025) Extensive Clinical Flow Cytometric Lymphocyte Phenotyping in Myasthenia Gravis: A Single-Center Study. *Journal of neurochemistry*, 169(6), e70126.

Roshal M, et al. (2025) Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Stenberg cells reveals escape from NK cell recognition and an unfolded protein response. *bioRxiv : the preprint server for biology*.

Kim WS, et al. (2024) A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Wu RQ, et al. (2023) Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. *Immunity*, 56(1), 180.

Mol JQ, et al. (2023) Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors. *iScience*, 26(7), 107183.

Piau O, et al. (2023) Generation of transgene-free hematopoietic stem cells from human induced pluripotent stem cells. *Cell stem cell*, 30(12), 1610.

Vadaq N, et al. (2022) Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV. *iScience*, 25(10), 105089.

Huang Z, et al. (2022) Increase of CD3+CD7- T cells in bone marrow predicts invasion in patients with T-cell non-Hodgkin's lymphoma. *Translational cancer research*, 11(6), 1463.

Ramzy A, et al. (2021) Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. *Cell stem cell*, 28(12), 2047.